Personalis (NASDAQ:PSNL) Trading 8.1% Higher – Should You Buy?

Shares of Personalis, Inc. (NASDAQ:PSNL) rose 8.1% on Wednesday . The company traded as high as $10.93 and last traded at $10.8740. 332,454 shares were traded during trading, a decline of 83% from the average daily volume of 1,942,976 shares. The stock had previously closed at $10.06.

Analyst Ratings Changes

A number of research analysts recently issued reports on PSNL shares. Morgan Stanley decreased their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. BTIG Research dropped their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Needham & Company LLC lifted their price objective on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Stock Up 10.8%

The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -12.34 and a beta of 2.28. The stock has a fifty day moving average of $8.29 and a 200-day moving average of $8.26.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. On average, equities analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 80,091 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $11.02, for a total transaction of $882,602.82. Following the transaction, the chief executive officer owned 235,986 shares of the company’s stock, valued at approximately $2,600,565.72. This trade represents a 25.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of Personalis stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $12.01, for a total value of $480,400.00. Following the sale, the chief financial officer owned 198,833 shares in the company, valued at $2,387,984.33. This trade represents a 16.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,799 shares of company stock worth $2,031,692 over the last quarter. 4.20% of the stock is owned by company insiders.

Institutional Trading of Personalis

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares during the period. Legal & General Group Plc purchased a new stake in Personalis in the second quarter valued at approximately $30,000. International Assets Investment Management LLC acquired a new stake in shares of Personalis in the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Finally, Focus Partners Wealth purchased a new position in shares of Personalis during the first quarter worth approximately $47,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.